These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 14728049

  • 1. Role of metabolically active drugs in the management of ischemic heart disease.
    Schofield RS, Hill JA.
    Am J Cardiovasc Drugs; 2001; 1(1):23-35. PubMed ID: 14728049
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Metabolic modulators for chronic cardiac ischemia.
    Parang P, Singh B, Arora R.
    J Cardiovasc Pharmacol Ther; 2005 Dec; 10(4):217-23. PubMed ID: 16382258
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Trimetazidine and the contractile response of dysfunctional myocardium in ischaemic cardiomyopathy.
    Belardinelli R.
    Rev Port Cardiol; 2000 Nov; 19 Suppl 5():V35-9. PubMed ID: 11206102
    [Abstract] [Full Text] [Related]

  • 9. Ranolazine: effects on ischemic heart.
    Rognoni A, Barbieri L, Cavallino C, Bacchini S, Veia A, Degiovanni A, Rametta F, Nardi F, Lazzero M, Lupi A, Bongo AS.
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
    [Abstract] [Full Text] [Related]

  • 10. Effectors of fatty acid oxidation reduction: promising new anti-ischaemic agents.
    Grynberg A.
    Curr Pharm Des; 2005 Dec; 11(4):489-509. PubMed ID: 15725067
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Partial fatty acid oxidation inhibitors for stable angina.
    Stanley WC.
    Expert Opin Investig Drugs; 2002 May; 11(5):615-29. PubMed ID: 11996644
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The antianginal agent trimetazidine does not exert its functional benefit via inhibition of mitochondrial long-chain 3-ketoacyl coenzyme A thiolase.
    MacInnes A, Fairman DA, Binding P, Rhodes Ja, Wyatt MJ, Phelan A, Haddock PS, Karran EH.
    Circ Res; 2003 Aug 08; 93(3):e26-32. PubMed ID: 12869391
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Metabolic management of ischaemic heart disease.
    Chierchia SL, Fragasso G.
    Eur Heart J; 1993 Nov 08; 14 Suppl G():2-5. PubMed ID: 7904560
    [Abstract] [Full Text] [Related]

  • 17. Metabolic support for the heart: complementary therapy for heart failure?
    Heggermont WA, Papageorgiou AP, Heymans S, van Bilsen M.
    Eur J Heart Fail; 2016 Dec 08; 18(12):1420-1429. PubMed ID: 27813339
    [Abstract] [Full Text] [Related]

  • 18. [Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism].
    Lopaschuk GD.
    Presse Med; 1998 Dec 12; 27(39):2100-4. PubMed ID: 9893703
    [Abstract] [Full Text] [Related]

  • 19. Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease.
    Mehta PK, Goykhman P, Thomson LE, Shufelt C, Wei J, Yang Y, Gill E, Minissian M, Shaw LJ, Slomka PJ, Slivka M, Berman DS, Bairey Merz CN.
    JACC Cardiovasc Imaging; 2011 May 12; 4(5):514-22. PubMed ID: 21565740
    [Abstract] [Full Text] [Related]

  • 20. Enhanced preservation of acutely ischemic myocardium and improved clinical outcomes using glucose-insulin-potassium (GIK) solutions.
    Lazar HL.
    Am J Cardiol; 1997 Aug 04; 80(3A):90A-93A. PubMed ID: 9293960
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.